Wells Fargo Maintains Overweight on Medtronic, Lowers Price Target to $102

Benzinga Newsdesk www.benzinga.com Negative 88.7%

Neg 88.7% Neu 0% Pos 0%

Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:MDT) with a Overweight and lowers the price target from $114 to $102.